Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 74

Sort by

Sort Order Select

Meeting Abstracts

895-P: Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate (ß-OHB)—Lack of Effect of Concomitant Insulin, GLP-1 Agonist, or Pioglitazone Therapy

LUIS C. ORTIZ, JOY WORTHAM, SHEILA PINKSON, JONATHAN TREJO, AMIEL S. MENDOZA, XI CHEN, DEVJIT TRIPATHY

Diabetes 2023;72(Supplement_1):895-P

https://doi.org/10.2337/db23-895-P

Published: 20 June 2023

View article titled, 895-P: Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate (ß-OHB)—Lack of Effect of Concomitant Insulin, GLP-1 Agonist, or Pioglitazone Therapy

Journal Articles

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Jennifer E. Nyland, Nazia T. Raja-Khan, Kerstin Bettermann, Philippe A. Haouzi, Douglas L. Leslie, Jennifer L. Kraschnewski, Leslie J. Parent, Patricia Sue Grigson

Diabetes 2021;70(12):2903–2916

https://doi.org/10.2337/db21-0385

Published: 27 September 2021

View article titled, Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Meeting Abstracts

1827-P: Pioglitazone Improves Nonalcoholic Steatohepatitis (NASH) in a Diet-Induced Cynomolgus Monkey Model

RAUL CAMACHO, DAVID POLIDORI, TAO CHEN, BIN GAO, PEGGY WONG, JOSEPH A. GABRIEL, EDWARD ZHU, TONY WANG, ANDREA R. NAWROCKI

Diabetes 2020;69(Supplement_1):1827-P

https://doi.org/10.2337/db20-1827-P

Published: 01 June 2020

View article titled, 1827-P: Pioglitazone Improves Nonalcoholic Steatohepatitis (NASH) in a Diet-Induced Cynomolgus Monkey Model

Meeting Abstracts

2148-PUB: Relationship between SGLT2 Inhibitor, ACEI/ARB, and Pioglitazone to Renal Function in Patients with Type 2 Diabetes Mellitus

TAO-CHUN LEE

Diabetes 2020;69(Supplement_1):2148-PUB

https://doi.org/10.2337/db20-2148-PUB

Published: 01 June 2020

View article titled, 2148-PUB: Relationship between SGLT2 Inhibitor, ACEI/ARB, and Pioglitazone to Renal Function in Patients with Type 2 Diabetes Mellitus

Meeting Abstracts

2208-PUB: Effect of Pioglitazone on HOMA-IR, C-Peptide, HbA1c, and Weight

SHRUTI V. SHETH, MALAY N. PAREKH, DHARMENDRA PANCHAL

Diabetes 2020;69(Supplement_1):2208-PUB

https://doi.org/10.2337/db20-2208-PUB

Published: 01 June 2020

View article titled, 2208-PUB: Effect of Pioglitazone on HOMA-IR, C-Peptide, HbA1c, and Weight

Meeting Abstracts

1945-P: Pioglitazone Promotes the Function of White and Brown Adipose Tissue in Diet-Induced Obese Mice

FEN XU, WEI WANG, XIAOBIN ZHENG, WANRONG GUO, YUNFENG SHEN

Diabetes 2020;69(Supplement_1):1945-P

https://doi.org/10.2337/db20-1945-P

Published: 01 June 2020

View article titled, 1945-P: Pioglitazone Promotes the Function of White and Brown Adipose Tissue in Diet-Induced Obese Mice

Journal Articles

Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes

Serena Tedesco, Stefano Ciciliot, Lisa Menegazzo, Marianna D’Anna, Valentina Scattolini, Roberta Cappellari, Andrea Cignarella, Angelo Avogaro, Mattia Albiero, Gian Paolo Fadini

Diabetes 2020;69(7):1562–1572

https://doi.org/10.2337/db19-0640

Published: 28 April 2020

View article titled, Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes

Journal Articles

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

William G. Tharp, Dhananjay Gupta, Olga Sideleva, Carolyn F. Deacon, Jens J. Holst, Dariush Elahi, Richard E. Pratley

Diabetes 2020;69(2):146–157

https://doi.org/10.2337/db18-1163

Published: 22 November 2019

View article titled, Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

Includes: Supplementary data

Meeting Abstracts

2082-P: Pharmacological Induction of Brown and Beige Adipose Tissue

BRIAN FINLIN, HASIYET MEMETIMIN, AMY L. CONFIDES, BEIBEI ZHU, ZACHARY R. JOHNSON, ESTHER E. DUPONT-VERSTEEGDEN, PHILIP A. KERN

Diabetes 2019;68(Supplement_1):2082-P

https://doi.org/10.2337/db19-2082-P

Published: 01 June 2019

View article titled, 2082-P: Pharmacological Induction of Brown and Beige Adipose Tissue

Meeting Abstracts

1122-P: Physiological Effects of Pioglitazone in Ataxia-Telangiectasia

LAURA J. MCCREIGHT, ANDREA MARI, EWAN PEARSON

Diabetes 2019;68(Supplement_1):1122-P

https://doi.org/10.2337/db19-1122-P

Published: 01 June 2019

View article titled, 1122-P: Physiological Effects of Pioglitazone in Ataxia-Telangiectasia

Meeting Abstracts

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

JULIO ROSENSTOCK, LAWRENCE BLONDE, STEFANO DEL PRATO, ROBERT R. HENRY, NAIM SHEHADEH, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, JUNLONG WU, XIANGLING WANG, CHEN JI, VANITA R. ARODA

Diabetes 2019;68(Supplement_1):1146-P

https://doi.org/10.2337/db19-1146-P

Published: 01 June 2019

View article titled, 1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

Meeting Abstracts

483-P: Pioglitazone Suppresses Macrophage Proliferation in Apolipoprotein-e Deficient Mice by Activating PPARγ

SAIKO MURAKAMI-NISHIDA, TAKESHI MATSUMURA, SHUHEI NISHIDA, TAKAFUMI SENOKUCHI, NORIO ISHII, SARIE YAMADA, YUTARO MORITA, TOSHIAKI WADA, HIROYUKI MOTOSHIMA, TATSUYA KONDO, EIICHI ARAKI

Diabetes 2019;68(Supplement_1):483-P

https://doi.org/10.2337/db19-483-P

Published: 01 June 2019

View article titled, 483-P: Pioglitazone Suppresses Macrophage Proliferation in Apolipoprotein-e Deficient Mice by Activating PPARγ

Meeting Abstracts

1840-P: Pioglitazone Increases Metabolic Insulin Clearance (MCRI) in IGT Subjects: The ACT NOW Study

AMALIA GASTALDELLI, DEVJIT TRIPATHY, RALPH A. DEFRONZO, NOW ACT INVESTIGATORS

Diabetes 2019;68(Supplement_1):1840-P

https://doi.org/10.2337/db19-1840-P

Published: 01 June 2019

View article titled, 1840-P: Pioglitazone Increases Metabolic Insulin Clearance (MCRI) in IGT Subjects: The ACT NOW Study

Meeting Abstracts

1861-P: Pioglitazone Modulates Hepatic Pyruvate Dehydrogenase and TCA Cycle Flux

CHRIS SHANNON, MUKUNDAN RAGAVAN, RALPH A. DEFRONZO, MATTHEW MERRITT, LUKE NORTON

Diabetes 2019;68(Supplement_1):1861-P

https://doi.org/10.2337/db19-1861-P

Published: 01 June 2019

View article titled, 1861-P: Pioglitazone Modulates Hepatic Pyruvate Dehydrogenase and TCA Cycle Flux

Meeting Abstracts

223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence

FERNANDO BRIL, ROMINA LOMONACO, SRILAXMI KALAVALAPALLI, JINPING LAI, KENNETH CUSI

Diabetes 2019;68(Supplement_1):223-OR

https://doi.org/10.2337/db19-223-OR

Published: 01 June 2019

View article titled, 223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence

Meeting Abstracts

2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model

FRANÇOIS BRIAND, EMMANUEL BROUSSEAU, THIERRY SULPICE

Diabetes 2019;68(Supplement_1):2004-P

https://doi.org/10.2337/db19-2004-P

Published: 01 June 2019

View article titled, 2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model

Meeting Abstracts

2320-PUB: Effects of Sequential Therapy Using Metformin plus Pioglitazone following Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed T2DM

LIEHUA LIU, LI HAI, WEIJIAN KE, YANBING LI

Diabetes 2019;68(Supplement_1):2320-PUB

https://doi.org/10.2337/db19-2320-PUB

Published: 01 June 2019

View article titled, 2320-PUB: Effects of Sequential Therapy Using Metformin plus Pioglitazone following Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed T2DM

Meeting Abstracts

A Pilot, Head-to-Head Comparison of Hydroxychloroquine (HCQ) with Pioglitazone (PIO) as Third-Line Agents in Type 2 Diabetic Patients Failing Metformin and a Sulfonylurea (SU)

STANLEY H. HSIA, PETRA DURAN, MAYER B. DAVIDSON

Diabetes 2018;67(Supplement_1):1172-P

https://doi.org/10.2337/db18-1172-P

Published: 01 July 2018

View article titled, A Pilot, Head-to-Head Comparison of Hydroxychloroquine (HCQ) with Pioglitazone (PIO) as Third-Line Agents in Type 2 Diabetic Patients Failing Metformin and a Sulfonylurea (SU)

Meeting Abstracts

Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study

MUHAMMAD ABDUL-GHANI, CURTISS L. PUCKETT, JR., CURTIS L. TRIPLITT, DAVID MAGGS, JOHN M. ADAMS, II, EUGENIO CERSOSIMO, RALPH A. DEFRONZO

Diabetes 2018;67(Supplement_1):123-OR

https://doi.org/10.2337/db18-123-OR

Published: 01 July 2018

View article titled, Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study

Meeting Abstracts

The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone

ANASTASIOS KOUTSOVASILIS, ALEXIOS SOTIROPOULOS, MARIA PAPPA, DESPINA PAPADAKI, VASILIS KORDINAS, CHARALAMPOS TAMVAKOS, MARIA BOURIKOU, STAVROS BOUSBOULAS, THEODOROS PEPPAS

Diabetes 2018;67(Supplement_1):1235-P

https://doi.org/10.2337/db18-1235-P

Published: 01 July 2018

View article titled, The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone

NARROW

895-P: Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate (ß-OHB)—Lack of Effect of Concomitant Insulin, GLP-1 Agonist, or Pioglitazone Therapy

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

1827-P: Pioglitazone Improves Nonalcoholic Steatohepatitis (NASH) in a Diet-Induced Cynomolgus Monkey Model

2148-PUB: Relationship between SGLT2 Inhibitor, ACEI/ARB, and Pioglitazone to Renal Function in Patients with Type 2 Diabetes Mellitus

2208-PUB: Effect of Pioglitazone on HOMA-IR, C-Peptide, HbA1c, and Weight

1945-P: Pioglitazone Promotes the Function of White and Brown Adipose Tissue in Diet-Induced Obese Mice

Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

2082-P: Pharmacological Induction of Brown and Beige Adipose Tissue

1122-P: Physiological Effects of Pioglitazone in Ataxia-Telangiectasia

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

483-P: Pioglitazone Suppresses Macrophage Proliferation in Apolipoprotein-e Deficient Mice by Activating PPARγ

1840-P: Pioglitazone Increases Metabolic Insulin Clearance (MCRI) in IGT Subjects: The ACT NOW Study

1861-P: Pioglitazone Modulates Hepatic Pyruvate Dehydrogenase and TCA Cycle Flux

223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence

2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model

2320-PUB: Effects of Sequential Therapy Using Metformin plus Pioglitazone following Short-Term Intensive Insulin Therapy in Patients with Newly Diagnosed T2DM

A Pilot, Head-to-Head Comparison of Hydroxychloroquine (HCQ) with Pioglitazone (PIO) as Third-Line Agents in Type 2 Diabetic Patients Failing Metformin and a Sulfonylurea (SU)

Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study

The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only